Atrial fibrillation and heart failure

Congestive Heart Failure

Volumn 15, Issue 1, 2009, Pages 24-30

  Larned, Joshua M ^a   Laskar, S Raja ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; METOPROLOL; PLACEBO;

ACUTE HEART INFARCTION; ARTIFICIAL HEART PACEMAKER; CARDIOVERSION; CATHETER ABLATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART RATE; HEART RHYTHM; HEART SURGERY; HEART VENTRICLE FUNCTION; HUMAN; ISCHEMIC HEART DISEASE; MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; QT PROLONGATION; REVIEW; SURVIVAL RATE; SYSTOLIC DYSFUNCTION; TREATMENT RESPONSE;

ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; HEART FAILURE; HUMANS; INCIDENCE; PROGNOSIS; RISK FACTORS; UNITED STATES;

EID: 59449087224     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2008.00041.x     Document Type: Review

References (48)

1. American Heart Association. Heart disease and stroke statistics - 2008 update. Dallas, TX: American Heart Association; 2008.
2. Prystowky E, Waldo A. Atrial fibrillation, atrial flutter, and atrial tachycardia. In: Fuster V, O'Rourke R, Walsh R, Poole-Wilson P, eds; King A, Roberts R, Nash I, Prystowsky E, associate eds. Hurst's The Heart. 12th ed. New York: McGraw-Hill; 2008:953-982.
3. Kannel W, Abbott R, Savage D, et al. Epidemiologic features of chronic atrial fibrillation: The Framingham Study. N Engl J Med. 1982;306:1018-1022.
4. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: The Rotterdam Study. Eur Heart J. 2006;27:949-953.
5. Benjamin E, Levy D, Vaziri S, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271:840-844.
6. Fonarow G. Overview of acutely decompensated congestive heart failure (ADHF): A report from the ADHERE registry. Heart Fail Rev. 2004;9:179-185.
7. De Ferrari G, Klersy C, Ferrerro P, et al. Atrial fibrillation in heart failure patients: Prevalence in daily practice and effect on the severity of symptoms. Data from the ALPHA study registry. Eur J Heart Fail. 2007;9:502-509.
8. Middlekauff H, Stevenson W, Stevenson L. Prognostic significance of atrial fibrillation in advanced heart failure: A study of 390 patients. Circulation. 1991;84:40-48.
9. Olsson L, Swedberg K, Ducharme A, et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: Results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol. 2006;47:1997-2004.
10. Dries D, Exner D, Gersh B, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: A retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1994;32:695-703.
11. Swedberg K, Olsson L, Charlesworth A, et al. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: Results from COMET. Eur Heart J. 2005;26:1303-1308.
12. Pizzetti F, Turazza F, Franzosi M, et al. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: The GISSI-3 data. Heart. 2001;86:527-532.
13. Singh S, Fletcher R, Fisher S, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med. 1995;333:77-82.
14. Tsang T, Gersh B, Appleton C, et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 men and women. J Am Coll Cardiol. 2002;40:1636-1644.
15. Fuster V, Ryden L, Cannom D, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Full text. Europace. 2006;8:651-745.
16. Wyse D, Waldo J, Domanski Y, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-1833.
17. Van Gelder I, Hagens V, Bosker H, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-1840.
18. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate control versus rhythm control in persistent atrial fibrillation: The Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41:1690-1696.
19. The AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. Circulation. 2004;109:1509-1513.
20. Deedwandia P, Singh B, Ellenbogen K, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: Observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy. Circulation. 1998;98:2574-2579.
21. Roy D. The atrial fibrillation in heart failure study (AF-CHF study). American Heart Association 2007 Scientific Sessions, Orlando, FL. November 6, 2007. Late-breaking clinical trials.
22. Pederson O, Bagger H, Keller N, et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flitter in patients with reduced left ventricular function: A Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation. 2001;104:292-296.
23. Garg R, Gorlin R, Smith T, et al. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525-533.
24. Matsuda M, Matsuda Y, Yamagishi T, et al. Effects of digoxin, propranolol, and verapamil on exercise in patients with chronic isolated atrial fibrillation. Cardiovasc Res. 1991;25:453-457.
25. Khand A, Rankin A, Martin W, et al. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation of patients in heart failure? J Am Coll Cardiol. 2003;42:1945-1951.
26. Olshansky B, Rosenfeld L, Warner A, et al. The Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study: Approaches to rate control in atrial fibrillation. J Am Coll Cardiol. 2004;43:1202-1208.
27. Van Veldhuisen D, Aass H, Allaf D, et al. Presence and development of atrial fibrillation in chronic heart failure: Experiences from the MERIT-HF Study. Eur J Heart Fail. 2006;8:539-546.
28. Joglar J, Acusta A, Shusterman N, et al. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: Retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J. 2001;142:498-501.
29. Lechat P, Hulot J, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation. 2001;103:1428-1433.
30. Hunt S, Baker D, Chin M, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). http://www.acc.org/clinical/ guidelines/failure/hf_index.htm (21 December 2004).
31. Fuster V, Rydén L, Cannom D, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). J Am Coll Cardiol. 2006;48:854-906.
32. Healey J, Baranchuck A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. J Am Coll Cardiol. 2005;45:1832-1839.
33. Anand K, Mooss A, Hee T, et al. Meta-analysis: Inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J. 2006;152:217-222.
34. Kay G, Ellenbogen K, Giudici M, et al. The ablate and pace trial: A prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. J. Interv Card Electrophysiol. 1998;2:121-135.
35. Knight B, Gersh B, Carlson M, et al. Role of permanent pacing to prevent atrial fibrillation: Science advisory from the American Heart Association Council on Clinical Cardiology (Subcommittee on Electrocardiography and Arrhythmias) and the Quality of Care and Outcomes Research Interdisciplinary Working Group, in collaboration with the Heart Rhythm Society. Circulation. 2005;111:240-243.
36. Wood MA, Brown-Mahoney C, Kay GN, et al. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: A meta-analysis. Circulation. 2000;101:1138-1144.
37. Tse H, Lau C. Long term effect of right ventricular pacing on myocardial perfusion and function. J Am Coll Cardiol. 1997;29:744-749.
38. Lee M, Dae M, Langberg J, et al. Effects of long term right ventricular apical pacing on left ventricular perfusion, innervation, function, and histology. J Am Coll Cardiol. 1994;24:225-232.
39. Leon A, Greenberg J, Kanuru N, et al. Cardiac resynchronization in patients with congestive heart failure and chronic atrial fibrillation: effect of upgrading to biventricular pacing after chronic right ventricular pacing. J Am Coll Cardiol. 2002;39:1258-1263.
40. Valls-Bertault V, Fatemi M, Gilard M, et al. Assessment of upgrading to biventricular pacing in patients with right ventricular pacing and congestive heart failure after atrioventricular junctional ablation for chronic atrial fibrillation. Europace. 2004;6:438-443.
41. Doshi R, Daoud E, Fellows C, et al. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol. 2005;16:1166-1167.
42. Hoppe U, Casares J, Eiskjaer H, et al. Effect of cardiac resynchronization therapy on the incidence of atrial fibrillation in patients with severe heart failure. Circulation. 2006;114:18-25.
43. Kies P, Leclerq C, Bleeker G, et al. Cardiac resynchronization therapy in chronic atrial fibrillation: Impact on left atrial size and reversal to sinus rhythm. Heart. 2006;92:490-494.
44. Padeletti L. Atrial fibrillation in heart failure patients implanted with a cardiac resynchronization therapy device: One-year results of the randomized MASCOT study. American Heart Association 2007 Scientific Sessions, Orlando, FL. November 6, 2007. Late-breaking clinical trials.
45. Finta B, Haines DE. Catheter ablation therapy for atrial fibrillation. Cardiol Clin. 2004;22:127-145,ix.
46. Calkins H, Brugada J, Packer D, et al. HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up: A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Europace. 2007;9:335-379.
47. Hsu L, Jais P, Sanders P, et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med. 2004;351:2373-2383.
48. Khargi K, Hutten B, Lemke B, et al. Surgical treatment of atrial fibrillation: A systematic review. Eur J Cardiothorac Surg. 2007;27:258-265.